Semaglutide and Empagliflozin Both Change Kidney Microstructure on MRI — But Their Combination Does Not
Semaglutide and empagliflozin each independently reduced kidney cortical ADC on MRI and decreased total kidney volume in patients with type 2 diabetes, but their combination did not show additive effects on ADC.
Quick Facts
What This Study Found
Semaglutide and empagliflozin each reduced kidney cortical ADC and total kidney volume, but their combination did not show additive ADC effects; changes were independent of GFR, albuminuria, and inflammation.
Key Numbers
32-week randomized trial; diffusion-weighted MRI and total kidney volume measured; semaglutide vs. empagliflozin vs. combination.
How They Did This
Post hoc analysis of a 32-week randomized trial. 80 patients with T2D and high CV risk randomized to 4 groups (n=20 each): placebo, empagliflozin, semaglutide, or combination. Kidney ADC and total kidney volume measured by MRI.
Why This Research Matters
Understanding how kidney-protective drugs work at the tissue level could optimize combination therapy strategies. The unexpected finding that combination therapy didn't enhance kidney MRI changes challenges assumptions about additive benefits.
The Bigger Picture
Advanced imaging is beginning to reveal the kidney-level effects of metabolic drugs that previously could only be measured by blood and urine markers. This represents a new frontier in understanding renoprotection — and the surprising combination results suggest the drugs may work through overlapping rather than complementary kidney pathways.
What This Study Doesn't Tell Us
Small sample (20 per group). Post hoc analysis. ADC interpretation is debated — may not specifically reflect fibrosis. 32-week duration may be insufficient. Combination group had sequential rather than simultaneous drug initiation. ADC changes did not correlate with clinical endpoints.
Questions This Raises
- ?Why does the semaglutide-empagliflozin combination not show additive kidney MRI changes?
- ?Does cortical ADC change reflect actual kidney fibrosis or other microstructural processes?
- ?Should DWI-MRI become a routine tool for monitoring kidney drug effects in diabetes?
Trust & Context
- Key Stat:
- 3-5% kidney volume reduction All active treatments (semaglutide, empagliflozin, combination) decreased total kidney volume in T2D patients
- Evidence Grade:
- Moderate evidence — randomized trial substudy with novel imaging endpoint, but small sample size and post hoc analysis limit conclusions.
- Study Age:
- Published in 2024. Uses advanced MRI techniques to investigate drug mechanisms in diabetic kidney disease.
- Original Title:
- Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type 2 diabetes: a post hoc analysis from a 32 week randomised trial.
- Published In:
- Diabetologia, 67(10), 2175-2187 (2024)
- Authors:
- Vernstrøm, Liv(2), Gullaksen, Søren(2), Sørensen, Steffen S, Ringgaard, Steffen, Laustsen, Christoffer, Birn, Henrik, Funck, Kristian L, Laugesen, Esben, Poulsen, Per L
- Database ID:
- RPEP-09440
Evidence Hierarchy
Frequently Asked Questions
Can MRI scans show how diabetes drugs protect the kidneys?
Yes — this study used a special type of MRI called diffusion-weighted imaging to look at kidney microstructure. Both semaglutide and empagliflozin individually caused measurable changes in kidney tissue and reduced kidney size — possibly reversing the early enlargement that diabetes causes.
Is it better to take both drugs together for kidney protection?
Surprisingly, the combination didn't show the expected additive kidney MRI changes that each drug showed individually. However, both drugs still reduced kidney volume when combined. More research is needed to understand whether the clinical kidney benefits of combination therapy are still additive even if the MRI signals aren't.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09440APA
Vernstrøm, Liv; Gullaksen, Søren; Sørensen, Steffen S; Ringgaard, Steffen; Laustsen, Christoffer; Birn, Henrik; Funck, Kristian L; Laugesen, Esben; Poulsen, Per L. (2024). Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type 2 diabetes: a post hoc analysis from a 32 week randomised trial.. Diabetologia, 67(10), 2175-2187. https://doi.org/10.1007/s00125-024-06228-y
MLA
Vernstrøm, Liv, et al. "Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type 2 diabetes: a post hoc analysis from a 32 week randomised trial.." Diabetologia, 2024. https://doi.org/10.1007/s00125-024-06228-y
RethinkPeptides
RethinkPeptides Research Database. "Effects of semaglutide, empagliflozin and their combination ..." RPEP-09440. Retrieved from https://rethinkpeptides.com/research/vernstrom-2024-effects-of-semaglutide-empagliflozin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.